Hepatocellular carcinoma (HCC) is the most common primary liver cancer and remains a major cause of cancer-related mortality worldwide. Systemic therapies, including targeted therapies and immune checkpoint inhibitors, have revolutionized the management of advanced HCC. Although the prognosis of patients with advanced HCC remains poor, significant progress has been made with recent advances in drug development, particularly with the introduction of effective treatments such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Indeed, treatment response varies significantly among patients, highlighting the need for robust biomarkers. In addition, the development of molecular driver-targeted therapies remains an active research focus as most genetic alterations observed in HCC are currently undruggable. Meeting these goals will require additional efforts to obtain histological material in clinical trials, in order to enable robust translational research. This review explores the current landscape of biomarkers of response to systemic treatments in HCC, including molecular, immune-based markers as well as circulating tumor DNA and highlights potential paths of improvement.
Citations
Citations to this article as recorded by
A novel signature of palmitoylation for predicting prognosis and therapeutic response of hepatocellular carcinoma Yun Li, Zhongquan Yi, Linhua Liu, Danping Huang Discover Oncology.2026;[Epub] CrossRef
Tislelizumab-induced hyperosmolar diabetic ketoacidosis complicated with rhabdomyolysis in hepatocellular carcinoma patients: case report Longjun Chen, Xiaojuan Zeng, Tianping Li Frontiers in Oncology.2026;[Epub] CrossRef
Functional Interpretation of Recurrent Genetic Variants in Hepatocellular Carcinoma: Molecular Consequences and Clinical Relevance Yuntao Ye, Zhulin Xu, Jiang Wang, Chunyu Chen, Yuan Peng, Bo Li, Shaoqiu Chen Human Mutation.2026;[Epub] CrossRef
Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine Yule Ma, Huigang Li, Huan Chen, Jinxin Xu, Ziyi Ye, Yuhang Li, Xiang Wu, Jinyan Chen, Chenghao Cao, Peiru Zhang, Ruijie Zhao, Jun Li, Cheng Zhu, Jianyong Zhuo, Shengjun Xu, Xiao Xu, Di Lu Alimentary Pharmacology & Therapeutics.2026; 64(4): 441. CrossRef
Varices and Hemorrhagic Events during Atezolizumab-bevacizumab Treatment: Reassurance with Caveats for Prognosis Hae Lim Lee Gut and Liver.2026; 20(4): 509. CrossRef
Correspondence to letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma” Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi Clinical and Molecular Hepatology.2026; 32(3): e424. CrossRef
Integrated genetic and epigenetic biomarker landscapes in hepatocellular carcinoma: From molecular mechanisms to translational precision oncology Doaa Mamdouh Aly, Asmaa Mohamed Fteah, Mohamed A. Elrefaiy, Hani E. Seddik Gene Reports.2026; 45: 102597. CrossRef
Acquired Genetic Variants, Not Tumor Mutation Burden, Drive Resistance to Immunotherapy in Hepatocellular Carcinoma Jinho Lee, Hye Won Lee, Mi Ri Park, Saeam Shin, Jong Rak Choi, Hye Jung Park, Kyung Joo Cho, Seung-Tae Lee, Jun Yong Park Liver Cancer.2026; : 1. CrossRef
Prognostic value of tumor microenvironment-based molecular subtypes in hepatocellular carcinoma patients undergoing surgery for spinal metastases: refining conventional scoring systems Bing Liang, Annan Hu, Jian Zhou, Juan Li, Jian Dong Clinical and Experimental Medicine.2025;[Epub] CrossRef
First
Prev
